Clobetasol
Administration, Topical
Betamethasone
Calendula
Nail Diseases
Rats, Hairless
Psoriasis
Lichen Planus, Oral
Glucocorticoids
Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. (1/67)
Corticosteroids (CS) are potent immunosuppressive agents that are known to affect T cell-mediated inflammation by the inhibition of proliferation and cytokine production, as well as the immunostimulatory function of monocytes and macrophages. Not much is known of the effect of corticosteroids on dendritic cells (DC), the professional T cell stimulatory antigen-presenting cells. We report that the endogenous CS hydrocortisone and the synthetic CS clobetasol-17-propionate strongly inhibited the production of the inflammatory mediators interleukin (IL)-12 p70, tumor necrosis factor alpha (TNF-alpha), and IL-6 by lipopolysaccharide (LPS)-stimulated monocyte-derived immature DC (iDC) in vitro. In contrast, the stimulatory capacity, antigen uptake, and the expression of costimulatory molecules were not affected. In accordance with the decreased production of IL-12 p70, CS-treated iDC induced less production of the inflammatory Th1 cytokine interferon-y and enhanced levels of the Th2 cytokines IL-10 and IL-5 in staphylococcal enterotoxin B-stimulated CD4+ Th cells. Furthermore, CS inhibited the maturation of iDC as assessed by the lack of expression of CD83 as well as by the prevention of the loss of antigen uptake capacities. These type 3 DC (DC3) matured in the presence of CS produce less IL-12 p70 and have a decreased T cell stimulatory capacity. Moreover, uncommitted T cells that encounter the CS-induced DC3 develop into Th2-biased cells, which may additionally decrease the Th1-mediated tissue damage but, on the other hand, Th2 cytokines may promote undesirable elevation of IgE and eosinophilia. These findings indicate that suppression of T cell-mediated inflammation by CS not only relies on direct effects on T cells, but also on various effects on DC, their professional antigen-presenting cells. (+info)Update on psoriasis therapy: a perspective from the USA. (2/67)
Because physicians from different nations frequently acquire the use of a new medication at different times, the international exchange of experiences with the new medication is valuable in maximizing its efficacy worldwide. In recent years, many new therapeutic agents have been approved for treating psoriasis in the United States. These include the topical agent calcipotriol and the systemic agents acitretin and cyclosporine. In addition to new agents, a new therapeutic paradigm, sequential therapy, has been introduced recently. It is the hope of the authors that by sharing this paradigm and experiences with these agents in the United States, dermatologists in Japan may gain further insight into optimizing the use of these agents in the treatment of psoriasis. (+info)Lichen planus. (3/67)
Lichen planus is an inflammatory mucocutaneous condition with characteristic violaceous polygonal flat-topped papules and plaques. Pruritus is often severe. Skin lesions may be disfiguring, and involvement of the oral mucosa or genital mucosa in severe cases may be debilitating. Oral lichen planus may predispose to the development of squamous cell carcinoma within lesions. Involvement of the scalp and the nails may also occur. While most cases of lichen planus are idiopathic, some may be caused by the ingestion of certain medications (e.g., gold, antimalarial agents, penicillamine, thiazide diuretics, beta blockers, nonsteroidal anti-inflammatory drugs, quinidine and angiotensin-converting enzyme inhibitors) or linked to hepatitis C virus infection. Patients with localized lichen planus are usually treated with potent topical steroids, while systemic steroids are used to treat patients with generalized lichen planus. (+info)Clinical features of lichen sclerosus in men attending a department of genitourinary medicine. (4/67)
OBJECTIVES: To characterise the clinical presentation and response to treatment of lichen sclerosus (LS) in men attending a department of genitourinary medicine. METHODS: A case note review of all men attending a GUM department over a 32 month period, who had been diagnosed as having LS. RESULTS: 66 men were seen with genital LS. The mean age at diagnosis was 36.5 years but symptoms had been present for up to 10 years before the diagnosis was made. 55 men underwent biopsy and the diagnosis was made histologically in 47 of these men. At the time of presentation 30% of men had no symptoms relating to their LS. All were treated with potent topical steroids and surgery was avoided in nearly all of them. CONCLUSIONS: LS is not uncommon in men presenting to a GUM department, and is often asymptomatic. The disease responds well to potent topical steroids allowing the normal anatomy to be preserved in most individuals. (+info)Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. (5/67)
1. This study examines the relative contributions made by inhibition of mast cell degranulation, reduction of mast cell recruitment and maturation, and lowering the responsiveness of the vasculature to histamine, in the inhibition by glucocorticoids of the weal and flare in human skin. 2. One forearm of healthy human volunteers was treated for 24 h (n=6) or daily for 21 days (n=10) with 0.05% clobetasol propionate. The other arm served as control. Weal and flare responses were elicited by intradermal injection of 20 microl of 0.3 mM codeine. The areas of the responses were measured using scanning laser Doppler imaging. Microdialysis was used to assess histamine release. Mast cell numbers and tissue histamine content were assessed in 4-mm punch biopsies. Histamine (20 microl of 1 microM i.d.) was used to assess the status of the vasculature. 3. No significant effects were seen at 24 h. At 21 days, clobetasol reduced the areas of the codeine-induced weal and flare responses by 59 and 58% respectively (both P=0.006). Mast cell numbers were reduced by 47%, (P=0.014) and total tissue histamine content by 52% (P=0.006). Codeine-induced histamine release was reduced by 44% (P=0.022). The weal, but not the flare, induced by histamine was significantly inhibited (P=0.019). Echography revealed a 15% thinning of the skin by clobetasol. 4. These results demonstrate that reduction of the weal and flare responses to codeine following clobetasol treatment, results primarily from reduced mast cell numbers and tissue histamine content rather than inhibition by corticosteroids of mast cell degranulation. (+info)Ultraviolet irradiation increases matrix metalloproteinase-8 protein in human skin in vivo. (6/67)
Humans express three distinct collagenases, MMP-1, MMP-8, and MMP-13, that initiate degradation of fibrillar type I collagen. We have previously reported that ultraviolet irradiation causes increased expression of MMP-1, but not MMP-13, in keratinocytes and fibroblasts in human skin in vivo. We report here that ultraviolet irradiation increases expression of MMP-8 in human skin in vivo. Western analysis revealed that levels of the full-length, 85 kDa proenzyme form of MMP-8 increased significantly within 8 h post ultraviolet irradiation (2 minimal erythema doses). Increased full-length MMP-8 protein was associated with infiltration into the skin of neutrophils, which are the major cell type that expresses MMP-8. Immunofluorescence revealed coexpression of MMP-8 and neutrophil elastase, a marker for neutrophils. Immunohistology demonstrated MMP-8 expression in neutrophils in the papillary dermis between 4 and 8 h post ultraviolet irradiation, and in the epidermis at 24 h post radiation. MMP-8 mRNA expression was not detected in nonirradiated or ultraviolet-irradiated human skin, indicating that increased MMP-8 following ultraviolet irradiation resulted from preexisting MMP-8 protein in infiltrating neutrophils. Pretreatment of skin with the glucocorticoid clobetasol, but not all-trans retinoic acid, significantly blocked ultraviolet-induced increases in MMP-8 protein levels, and neutrophil infiltration. In contrast, all-trans retinoic acid and clobetasol were equally effective in blocking ultraviolet induction of MMP-1 and degradation of collagen in human skin in vivo. Taken together, these data demonstrate that ultraviolet irradiation increases MMP-8 protein, which exists predominantly in a latent form within neutrophils, in human skin in vivo. Although ultraviolet irradiation induces both MMP-1 and MMP-8, ultraviolet-induced collagen degradation is initiated primarily by MMP-1, with little, if any, contribution by MMP-8. (+info)A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. (7/67)
BACKGROUND: Bullous pemphigoid is the most common autoimmune blistering skin disease of the elderly. Because elderly people have low tolerance for standard regimens of oral corticosteroids, we studied whether highly potent topical corticosteroids could decrease mortality while controlling disease. METHODS: A total of 341 patients with bullous pemphigoid were enrolled in a randomized, multicenter trial and stratified according to the severity of their disease (moderate or extensive). Patients were randomly assigned to receive either topical clobetasol propionate cream (40 g per day) or oral prednisone (0.5 mg per kilogram of body weight per day for those with moderate disease and 1 mg per kilogram per day for those with extensive disease). The primary end point was overall survival. RESULTS: Among the 188 patients with extensive bullous pemphigoid, topical corticosteroids were superior to oral prednisone (P=0.02). The one-year survival rate was 76 percent in the topical-corticosteroid group and 58 percent in the oral-prednisone group. Disease was controlled at three weeks in 92 of the 93 patients in the topical-corticosteroid group (99 percent) and 86 of the 95 patients in the oral-prednisone group (91 percent, P=0.02). Severe complications occurred in 27 of the 93 patients in the topical-corticosteroid group (29 percent) and in 51 of the 95 patients in the oral-prednisone group (54 percent, P=0.006). Among the 153 patients with moderate bullous pemphigoid, there were no significant differences between the topical-corticosteroid group and the oral-prednisone group in terms of overall survival, the rate of control at three weeks, or the incidence of severe complications. CONCLUSIONS: Topical corticosteroid therapy is effective for both moderate and severe bullous pemphigoid and is superior to oral corticosteroid therapy for extensive disease. (+info)Cushing's syndrome caused by topical steroid therapy for psoriasis. (8/67)
A 72-year-old woman developed manifestations of Cushing's syndrome after long-term topical steroid therapy for psoriasis. Shortly after tapering the dose of topical steroids she developed signs of adrenal insufficiency (provoked by a urinary tract infection) requiring intravenous administration of a stress dose of hydrocortisone. There have only been a few reports of systemic side effects of topically applied corticosteroids in adults. Considering their serious consequences physicians should be alert to signs of Cushing's syndrome in patients on long-term topical steroid therapy. Furthermore, clobetasol propionate ointment doses exceeding 50 g a week should not be prescribed and use of occlusive dressings should be avoided. (+info)1. Onychomycosis: This is a fungal infection of the nail that can cause discoloration, thickening, and brittleness of the nails. It is more common in toenails than fingernails.
2. Paronychia: This is a bacterial or fungal infection of the skin around the nail that can cause redness, swelling, and pus.
3. Nail psoriasis: This is a chronic condition that causes redness, thickening, and pitting of the nails. It is often associated with psoriasis, an autoimmune disorder.
4. Nail trauma: This can occur due to injury or repetitive stress on the nail, such as from biting or picking at the nails.
5. Nail cancer: This is a rare condition that affects the skin underneath the nail and can cause thickening, discoloration, and bleeding.
6. Melanonychia: This is a condition where the nails become darkened due to an increase in melanin production. It can be caused by a variety of factors, including exposure to ultraviolet radiation, certain medications, and underlying medical conditions.
7. Nail fragility: This is a condition where the nails are weak and prone to breaking or splitting. It can be caused by a variety of factors, including nutritional deficiencies, systemic diseases, and trauma.
8. Nail abnormalities: These can occur due to a variety of factors, including genetics, infections, and certain medical conditions. Examples include clubbing of the nails, where the nails curve downward, and koilonychia, where the nails are thin and concave.
Nail diseases can be diagnosed through a combination of physical examination, medical history, and diagnostic tests such as nail scrapings, biopsies, or blood tests. Treatment depends on the underlying cause of the condition and may involve topical or oral medications, changes to the diet or lifestyle, or surgery in severe cases. It is important to seek medical attention if you notice any changes or abnormalities in your nails, as early diagnosis and treatment can help prevent complications and improve outcomes.
Some common types of hand dermatoses include:
1. Contact dermatitis: This is a type of eczema that occurs when the skin comes into contact with an irritant or allergen. It can cause redness, itching, and dryness on the hands.
2. Psoriasis: This is a chronic condition that causes red, scaly patches on the skin. It can affect any part of the body, including the hands.
3. Eczema: This is a general term for a group of conditions that cause dry, itchy skin. It can affect the hands as well as other parts of the body.
4. Dermatitis herpetiformis: This is a condition that causes small blisters or bumps on the skin, often in conjunction with other symptoms such as fever and joint pain.
5. Urticaria: This is a condition that causes hives or itchy, raised welts on the skin. It can be caused by a variety of factors, including allergies, infections, and environmental exposures.
6. Angioedema: This is a condition that causes swelling of the deeper layers of skin, often in conjunction with hives or other symptoms.
7. Necrobiosis lipoidica diabeticorum: This is a condition that affects people with diabetes and causes raised, darkened areas on the skin, often on the hands and feet.
8. Hand eczema: This is a type of eczema that specifically affects the hands, causing dryness, itching, and redness on the palms and soles.
Treatment for hand dermatoses depends on the underlying cause and can include topical creams or ointments, medications, and lifestyle changes such as avoiding irritants and allergens, keeping the hands moisturized, and protecting them from extreme temperatures. In some cases, surgery may be necessary to remove affected skin or repair damaged tissue.
It is important to seek medical attention if you experience any persistent or severe symptoms on your hands, as early diagnosis and treatment can help prevent complications and improve outcomes.
Psoriasis can affect any part of the body, including the scalp, elbows, knees, and lower back. The symptoms of psoriasis can vary in severity, and the condition can have a significant impact on quality of life. In addition to physical discomfort, psoriasis can also cause emotional distress and stigma.
There is no cure for psoriasis, but there are several treatment options available, including topical creams and ointments, light therapy, and systemic medications such as biologic drugs. With proper treatment, many people with psoriasis are able to manage their symptoms and improve their quality of life.
Psoriasis is relatively common, affecting approximately 2-3% of the global population, with a higher prevalence in Caucasians than in other races. It can occur at any age, but typically starts in the late teenage years or early adulthood. Psoriasis is often associated with other health conditions, such as diabetes, heart disease, and depression.
Overall, psoriasis is a complex and multifactorial condition that requires a comprehensive approach to management, including both physical and emotional support. With appropriate treatment and self-care, people with psoriasis can lead full and active lives.
The exact cause of oral lichen planus is not known, but it is believed to be triggered by an allergic reaction or a viral or bacterial infection. It can affect anyone, but it is more common in women than men, and typically develops between the ages of 30 and 50.
The symptoms of oral lichen planus can vary from person to person, but they often include:
* Painful, inflamed lesions inside the mouth (on the tongue, lips, gums, or cheeks) that may be white, red, or purple in color.
* Burning sensation or stinging in the mouth.
* Difficulty eating or speaking due to pain and discomfort.
* Glossitis (inflammation of the tongue).
* Stomatitis (inflammation of the mouth).
* Ulcers or sores inside the mouth.
There is no cure for oral lichen planus, but there are several treatment options available to manage the symptoms and prevent complications. These may include:
* Topical medications (such as corticosteroids) applied directly to the affected areas in the mouth.
* Oral medications (such as antihistamines or immunosuppressants) to reduce inflammation and suppress the immune system.
* Phototherapy (exposure to specific wavelengths of light) to promote healing and reduce inflammation.
* Laser therapy to remove lesions and promote healing.
* Dietary changes to avoid spicy or acidic foods that may irritate the mouth.
While oral lichen planus is not a life-threatening condition, it can have a significant impact on quality of life, causing pain, discomfort, and difficulty eating and speaking. If you suspect you may have oral lichen planus, it is important to consult a dentist or healthcare professional for an accurate diagnosis and appropriate treatment.
Gingivitis can be treated with good oral hygiene practices, such as brushing and flossing regularly, and by visiting a dentist for regular check-ups and professional cleanings. If left untreated, gingivitis can progress to periodontitis, a more severe form of gum disease that can lead to permanent damage and tooth loss.
Some common symptoms of gingivitis include:
* Red and swollen gums
* Bleeding during brushing or flossing
* Bad breath
* Tenderness or pain in the gums
* A decrease in the amount of saliva
Treatment for gingivitis typically involves a combination of good oral hygiene practices and professional dental care. This may include:
* Regular brushing and flossing to remove plaque and bacteria from the teeth
* Professional cleanings ( scaling and root planing) to remove plaque and tartar from the teeth
* Antibiotics to treat any underlying infections
* Changes to diet and lifestyle to reduce the risk of further irritation to the gums.
It's important to note that while gingivitis is a mild form of gum disease, it can still have serious consequences if left untreated. Regular dental check-ups and good oral hygiene practices are essential for preventing and treating gingivitis.
Clobetasol
Clobetasol propionate
CYP3A5
Brian V. Jegasothy
Gestational pemphigoid
Antonella Tosti
Alopecia universalis
Pemphigoid
Plasma cell gingivitis
Scar
Pyoderma gangrenosum
Foreskin
Corticosteroid
Lichen sclerosus
Cheilitis
Betamethasone dipropionate
Mucous membrane pemphigoid
Pediatric gynaecology
Vulvitis
Finger tip unit
Clobetasone
Rebound effect
Open flow microperfusion
Alopecia areata
Dermatitis
Bullous pemphigoid
Lichen planus
Pemphigus
List of corticosteroid esters
ATC code D07
DailyMed - CLOBETASOL PROPIONATE solution
DailyMed - CLOBETASOL PROPIONATE lotion
Clobetasol Topical: MedlinePlus Drug Information
MedlinePlus - Search Results for: clobetasol
Clobex (clobetasol) dosing, indications, interactions, adverse effects, and more
Bedbug Bites Medication: Corticosteroids, Antihistamines
DailyMed - CICLOPIROX 1% / CLOBETASOL PROPIONATE 0.05% shampoo
Topinate Cream | Clobetasol Propionate | Erectile Wellness
Clobetasol Propionate - Cream - NorthstarRx LLC Pharmaceuticals
Dermochem (Clobetasol Propionate)
- The House Of Goodies
BP clobetasol impurity A | CAS# 5534-13-4 | C25H33FO6
How to use clobetasol propionate on scalp, using steroids on scalp - Первая Клининговая Компания
KAMREE ANTI DANDRUFF SCALP SERUM| Remove Fungus infection ,Clean Scalp Dandruff with 2% Salicylic Acid ,Clobetasol Propionate |...
NIH Clinical Center Search the Studies: Study Number, Study Title
Browsing by Subject
Clobex - Uses, Side Effects, Interactions - MedBroadcast.com
Desoximetasone - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf
JDH Pharmaceutical products
Licorice - Health Information Library | PeaceHealth
WHO EMRO | Misuse of topical corticosteroids: a clinical study in an Iraqi hospital | Volume 12, issue 6 | EMHJ volume 12, 2006
Genital allergy | Sexually Transmitted Infections
Cutaneous Leishmaniasis Acquired in Jura, France - Volume 18, Number 1-January 2012 - Emerging Infectious Diseases journal - CDC
How Much Does Dupixent Cost Without Insurance?
Contact dermatitis Disease Reference Guide - Drugs.com
Shop - Page 4 of 5 - Lupin Pharmaceuticals, Inc.
0.053
- Clobetasol propionate lotion, 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, in patients 18 years of age or older ( 1.1 ). (nih.gov)
- Clobetasol propionate lotion, 0.05% should be applied directly onto the affected skin areas twice daily and rubbed in gently. (nih.gov)
- 14. Vena GA, Cassano N, D'Argento V, Milani M. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, doubleblind, placebo-controlled trial. (bvsalud.org)
Corticosteroids3
- Local adverse reactions with topical corticosteroids may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, including clobetasol propionate. (nih.gov)
- Clobetasol is in a class of medications called corticosteroids. (medlineplus.gov)
- Almost 40 patients described their treatment, mostly with topical lotions containing clobetasol or minoxidil, and one with low-dose systemic corticosteroids. (news-medical.net)
Propionate lotion3
- These highlights do not include all the information needed to use CLOBETASOL PROPIONATE LOTION safely and effectively. (nih.gov)
- See full prescribing information for CLOBETASOL PROPIONATE LOTION. (nih.gov)
- Prominent & Leading Wholesale Trader from Nagpur, we offer elocon mometasone furoate ointment and clotic clobetasol propionate lotion. (apnamedex.com)
Ointment2
- To use clobetasol topical, apply a small amount of cream, ointment, gel, lotion, foam, or spray to cover the affected area of skin with a thin even film and rub it in gently. (medlineplus.gov)
- Clop-S Ointment is a topical medicine that consists of Clobetasol and Salicylic Acid. (practo.com)
Scalp10
- Clobetasol topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various scalp and skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). (medlineplus.gov)
- Optimal dosages of HGH can produce the following beneficial effects in patients affected by deficiencies, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- He s been a moderator on forums for over 10 years, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- It is important to note that both Winstrol and Dianabol can have side effects, particularly at higher dosages, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- Will anavar show up on a military drug test, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- How to use clobetasol propionate on scalp, cheap price order steroids online worldwide shipping. (1cleaningkom.ru)
- NO also acts directly on muscle fibres to alter cell function, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- Testosterone undecanoate and anavar cycle Anavar is an oral steroid which contains 10 mg of the hormone Oxandrolone, how to use clobetasol propionate on scalp. (1cleaningkom.ru)
- Clobetasol scalp applications should not be used near an open flame. (medbroadcast.com)
- A thin film of clobetasol shampoo should be applied directly to the affected area of the scalp once daily. (medbroadcast.com)
Topical corticosteroid2
- Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the hypothalamic-pituitary- adrenal (HPA) axis at the lowest doses tested. (nih.gov)
- Treatment of moderate to severe plaque psoriasis Clobetasol propionate is a super-high potency topical corticosteroid. (odanlab.com)
Redness1
- Clobetasol works by reducing swelling, redness, and itching. (medbroadcast.com)
Shampoo2
- Clobetasol shampoo is usually applied once a day. (medlineplus.gov)
- You may wash your hair as usual after applying and rinsing off clobetasol shampoo. (medlineplus.gov)
Foam3
- Before using clobetasol foam the first time, carefully read the written instructions that come with it. (medlineplus.gov)
- Clobetasol foam may catch fire. (medlineplus.gov)
- Stay away from open fire, flames, and do not smoke while you are applying clobetasol foam, and for a short time afterward. (medlineplus.gov)
Ingredients1
- tell your doctor and pharmacist if you are allergic to clobetasol, any other medications, or any of the ingredients in clobetasol topical products. (medlineplus.gov)
Medication1
- When clobetasol 17 - propionate is used over extensive areas for prolonged periods or under dressings that don't breathe, it is possible that enough medication will absorb into the bloodstream to cause unwanted side effects. (medbroadcast.com)
Medicine1
- Clobetasol propionate is a medicine that's used on the skin to treat swelling, itching, and irritation. (thehouseofgoodies.com)
Doctor2
- If you become pregnant while using clobetasol topical, call your doctor. (medlineplus.gov)
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are using clobetasol topical. (medlineplus.gov)
Propionate9
- These highlights do not include all the information needed to use CLOBETASOL PROPIONATE SHAMPOO safely and effectively. (nih.gov)
- See full prescribing information for CLOBETASOL PROPIONATE SHAMPOO. (nih.gov)
- Clobetasol propionate shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older. (nih.gov)
- Clobetasol propionate shampoo, 0.05% should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing. (nih.gov)
- Clobetasol propionate shampoo should not be used with a shower cap or bathing cap. (nih.gov)
- Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis at the lowest doses tested. (nih.gov)
- If a favorable response does not occur promptly, use of clobetasol propionate shampoo should be discontinued until the infection has been adequately controlled. (nih.gov)
- Local adverse reactions with topical corticosteroids may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, including clobetasol propionate. (nih.gov)
- 8. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. (nih.gov)
Allergic to clobetasol2
- tell your doctor and pharmacist if you are allergic to clobetasol, any other medications, or any of the ingredients in clobetasol topical products. (medlineplus.gov)
- Individuals at least 12 years of age who have oral GHVD and are not allergic to clobetasol. (nih.gov)
Topical7
- Clobetasol topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various scalp and skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). (medlineplus.gov)
- Use clobetasol topical exactly as directed. (medlineplus.gov)
- Do not let clobetasol topical get into your eyes or mouth and do not swallow it. (medlineplus.gov)
- You should wash your hands after applying clobetasol topical. (medlineplus.gov)
- If you become pregnant while using clobetasol topical, call your doctor. (medlineplus.gov)
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are using clobetasol topical. (medlineplus.gov)
- Patients currently using clobetasol oral topical treatment are not eligible for this study. (nih.gov)
Steroid2
Time2
- Before using clobetasol foam the first time, carefully read the written instructions that come with it. (medlineplus.gov)
- Stay away from open fire, flames, and do not smoke while you are applying clobetasol foam, and for a short time afterward. (medlineplus.gov)
Oral1
- To see if a clobetasol rinse is a safe and effective treatment for oral graft-versus-host disease. (nih.gov)